DK0797666T3 - Genetisk manipulerede humane Kunitz-domæner, der inhiberer human neutrofil elastase - Google Patents

Genetisk manipulerede humane Kunitz-domæner, der inhiberer human neutrofil elastase

Info

Publication number
DK0797666T3
DK0797666T3 DK95943819T DK95943819T DK0797666T3 DK 0797666 T3 DK0797666 T3 DK 0797666T3 DK 95943819 T DK95943819 T DK 95943819T DK 95943819 T DK95943819 T DK 95943819T DK 0797666 T3 DK0797666 T3 DK 0797666T3
Authority
DK
Denmark
Prior art keywords
neutrophil elastase
genetically engineered
human
kunitz domains
inhibit
Prior art date
Application number
DK95943819T
Other languages
English (en)
Inventor
Bruce Lindsay Roberts
William Markland
Robert Charles Ladner
Sonia Kosow Guterman
Arthur Charles Ley
Rachel Baribault Kent
Original Assignee
Dyax Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dyax Corp filed Critical Dyax Corp
Application granted granted Critical
Publication of DK0797666T3 publication Critical patent/DK0797666T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43522—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from scorpions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/805—Haemoglobins; Myoglobins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Insects & Arthropods (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK95943819T 1994-12-16 1995-12-15 Genetisk manipulerede humane Kunitz-domæner, der inhiberer human neutrofil elastase DK0797666T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/358,160 US5663143A (en) 1988-09-02 1994-12-16 Engineered human-derived kunitz domains that inhibit human neutrophil elastase

Publications (1)

Publication Number Publication Date
DK0797666T3 true DK0797666T3 (da) 2006-04-03

Family

ID=23408531

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95943819T DK0797666T3 (da) 1994-12-16 1995-12-15 Genetisk manipulerede humane Kunitz-domæner, der inhiberer human neutrofil elastase

Country Status (9)

Country Link
US (1) US5663143A (da)
EP (2) EP1734121A3 (da)
JP (1) JP3977419B2 (da)
AT (1) ATE311452T1 (da)
CA (1) CA2207820A1 (da)
DE (1) DE69534656T2 (da)
DK (1) DK0797666T3 (da)
ES (1) ES2255066T3 (da)
WO (1) WO1996020278A2 (da)

Families Citing this family (171)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060134087A1 (en) * 1988-09-02 2006-06-22 Dyax Corp. ITI-D1 Kunitz domain mutants as hNE inhibitors
US7078383B2 (en) * 1988-09-02 2006-07-18 Dyax Corp. ITI-D1 Kunitz domain mutants as HNE inhibitors
ES2113940T3 (es) * 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
ATE529444T1 (de) * 1994-01-11 2011-11-15 Dyax Corp Inhibitoren des humanplasmins, die sich von den kunitz domänen ableiten
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
PT744958E (pt) 1994-01-31 2003-11-28 Univ Boston Bancos de anticorpos policlonais
US20060078561A1 (en) * 1994-01-31 2006-04-13 The Trustees Of Boston University Polyclonal antibody libraries
US6010861A (en) * 1994-08-03 2000-01-04 Dgi Biotechnologies, Llc Target specific screens and their use for discovering small organic molecular pharmacophores
US5780265A (en) * 1995-06-05 1998-07-14 Genentech, Inc. Kunitz type plasma kallikrein inhibitors
US5786328A (en) * 1995-06-05 1998-07-28 Genentech, Inc. Use of kunitz type plasma kallikrein inhibitors
US20030199450A1 (en) * 2001-04-27 2003-10-23 Chiron Corporation Regulation of cytokine synthesis and release
US6242414B1 (en) * 1995-06-07 2001-06-05 Chiron Corporation Regulation of cytokine synthesis and release
WO1997033996A2 (en) 1996-03-11 1997-09-18 Bayer Corporation Human bikunin
US5985543A (en) * 1996-10-11 1999-11-16 The Trustees Of The University Of Pennsylvania Compositions and methods for detection of antibody binding to cells
US5876925A (en) * 1996-10-11 1999-03-02 The Trustees Of The University Of Pennsylvania Magnetically activated cell sorting for production of proteins
WO1998033920A2 (en) * 1997-01-31 1998-08-06 Human Genome Sciences, Inc. Tissue factor pathway inhibitor-3
AU4070499A (en) 1998-04-30 1999-11-16 Cornell Research Foundation Inc. Adenoviral vectors with tandem fiber proteins
EP1082431A2 (en) * 1998-06-03 2001-03-14 Scios Inc. Protease inhibitor peptides
CA2334170A1 (en) 1998-07-27 2000-02-10 Genentech, Inc. Improved transformation efficiency in phage display through modification of a coat protein
US6455314B1 (en) 1998-09-11 2002-09-24 Genvec, Inc. Alternatively targeted adenovirus
US20070140979A1 (en) * 1998-12-22 2007-06-21 Bayer Aktiengesellschaft Method for accelerating the rate of mucociliary clearance
WO2000037099A2 (en) * 1998-12-22 2000-06-29 Bayer Aktiengesellschaft Method for accelerating the rate of mucociliary clearance by using a kunitz-type serine protease inhibitor
US6294648B1 (en) * 1999-07-20 2001-09-25 Bayer Corporation Protein having proteinase inhibitor activity
EP1240319A1 (en) * 1999-12-15 2002-09-18 Genentech, Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
AU2001265154A1 (en) * 2000-05-31 2001-12-11 Genvec, Inc. Method and composition for targeting an adenoviral vector
US20020150594A1 (en) * 2000-06-26 2002-10-17 Maxygen, Inc. Methods and compositions for developing spore display systems for medicinal and industrial applications
EP1184393A1 (en) * 2000-09-04 2002-03-06 Debiopharm S.A. Process for the purification of EPI-HNE proteins
DE60131757T2 (de) 2000-09-04 2008-11-06 Debiopharm S.A. Verfahren zur reinigung von epi-hne proteinen
WO2002036158A1 (en) * 2000-10-31 2002-05-10 Debiopharm S.A. Suspension of an epi-hne protein, process of preparation thereof, dry powder aerosol derived therefrom, pharmaceutical compositions containing said suspension or aerosol, and their uses
EP1201249A1 (en) * 2000-10-31 2002-05-02 Debiopharm S.A. Suspension of EPI-HNE-4, dry powder aerosol derived therefrom, process of preparation thereof, pharmaceutical compositions containing said suspension or aerosol, and their uses
US20040175756A1 (en) * 2001-04-26 2004-09-09 Avidia Research Institute Methods for using combinatorial libraries of monomer domains
US20050048512A1 (en) * 2001-04-26 2005-03-03 Avidia Research Institute Combinatorial libraries of monomer domains
US20050053973A1 (en) * 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
JP4369662B2 (ja) * 2001-04-26 2009-11-25 アビディア インコーポレイテッド 単量体ドメインのコンビナトリアルライブラリー
US20060223114A1 (en) * 2001-04-26 2006-10-05 Avidia Research Institute Protein scaffolds and uses thereof
US20050089932A1 (en) * 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
US20030157561A1 (en) * 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
WO2005010044A2 (en) 2003-07-08 2005-02-03 Genentech, Inc. Il-17 a/f heterologous polypeptides and therapeutic uses thereof
KR100576674B1 (ko) 2001-06-20 2006-05-10 제넨테크, 인크. 종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
US7803915B2 (en) 2001-06-20 2010-09-28 Genentech, Inc. Antibody compositions for the diagnosis and treatment of tumor
ES2431929T3 (es) 2001-09-18 2013-11-28 Genentech, Inc. Composiciones y procedimientos para el diagnóstico y el tratamiento de tumores
EP2067472A1 (en) 2002-01-02 2009-06-10 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
AU2003210220A1 (en) * 2002-01-23 2003-09-02 Debiopharm Sa Production of epi-hne-4 comprising reduction of improperly processed form
CA2475382A1 (en) * 2002-02-07 2003-08-14 Delta Biotechnology Limited Albumin-fused anti-angiogenesis peptides
US20050222023A1 (en) * 2002-02-07 2005-10-06 Hans-Peter Hauser Albumin-fused kunitz domain peptides
CA2481507A1 (en) 2002-04-16 2003-10-30 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP2305710A3 (en) 2002-06-03 2013-05-29 Genentech, Inc. Synthetic antibody phage libraries
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
DK2311432T3 (da) 2002-06-07 2015-02-02 Dyax Corp Modificerede Kunitz-domæne-polypeptider og deres anvendelse til reduktion af iskæmi eller indtræden af en systemisk inflammatorisk reaktion i forbindelse med en kirurgisk procedure
MXPA05002287A (es) * 2002-08-29 2005-08-18 Genentech Inc 2 polipeptidos similares a achaete-scute y acidos nucleicos de codificacion, y metodos para el diagnostico y tratamiento de tumores.
US6989369B2 (en) * 2003-02-07 2006-01-24 Dyax Corp. Kunitz domain peptides
AU2004268145B2 (en) * 2003-08-29 2010-09-16 Takeda Pharmaceutical Company Limited Poly-PEGylated protease inhibitors
AU2004268144A1 (en) * 2003-08-29 2005-03-10 Dyax Corp. Modified protease inhibitors
WO2005040229A2 (en) * 2003-10-24 2005-05-06 Avidia, Inc. Ldl receptor class a and egf domain monomers and multimers
PL2295073T3 (pl) 2003-11-17 2014-09-30 Genentech Inc Przeciwciało przeciwko CD22 do leczenia nowotworu pochodzącego z układu krwiotwórczego
EP1732593A1 (en) * 2004-03-31 2006-12-20 Coloplast A/S Use of epi-hne 1-4
EP1789453A2 (en) * 2004-05-18 2007-05-30 Genentech, Inc. M13 virus major coat protein variants for c-terminal and bi-terminal display of a heterologous protein
EP1771212A1 (en) * 2004-07-16 2007-04-11 Coloplast A/S A wound care device
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
CA2587775A1 (en) * 2004-11-22 2006-06-01 Dyax Corp. Plasmin-inhibitory therapies
US8841259B2 (en) * 2005-02-24 2014-09-23 Joslin Diabetes Center Compositions and methods for treating vascular permeability
EP1869076A2 (en) 2005-03-10 2007-12-26 Genentech, Inc. Methods and compositions for modulating vascular integrity
CA2610709A1 (en) 2005-06-06 2006-12-14 Genentech, Inc. Transgenic models for different genes and their use for gene characterization
TW200745159A (en) * 2005-07-13 2007-12-16 Avidia Inc IL-6 binding proteins
AU2006280321A1 (en) 2005-08-15 2007-02-22 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
GB0521404D0 (en) * 2005-10-20 2005-11-30 Ares Trading Sa Kunitz domain containing protein
EP1962584A2 (en) 2005-11-21 2008-09-03 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
AU2006342792A1 (en) 2005-12-02 2007-11-08 Genentech, Inc. Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to IL-22 and IL-22R
US8828703B2 (en) 2005-12-29 2014-09-09 Dyax Corp. Protease inhibition
DK1976985T3 (da) 2005-12-29 2013-10-21 Univ California Fremgangsmåder og præparater relateret til mutant Kunitz-domæne I af TFPI-2
AU2007233263A1 (en) 2006-02-17 2007-10-11 Genentech, Inc. Gene disruptons, compositions and methods relating thereto
AU2007243946B2 (en) 2006-04-05 2012-11-29 Curis, Inc. Method for using BOC/CDO to modulate hedgehog signaling
EP2082645A1 (en) 2006-04-19 2009-07-29 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
US20090142259A1 (en) * 2006-05-12 2009-06-04 Genentech, Inc. Compositions and methods for the diagnosis and treatment of bladder and urinary tract tumors
JP5244103B2 (ja) 2006-08-09 2013-07-24 ホームステッド クリニカル コーポレイション 器官特異的蛋白質およびその使用方法
ES2372217T3 (es) 2006-09-12 2012-01-17 Genentech, Inc. Procedimientos y composiciones para el diagnóstico y tratamiento del cáncer de pulmón utilizando el gen de pdgfra, kit o kdr como marcador genético.
JPWO2008032833A1 (ja) 2006-09-14 2010-01-28 株式会社医学生物学研究所 Ａｄｃｃ活性を増強させた抗体及びその製造方法
US20100119512A1 (en) * 2007-01-25 2010-05-13 Joslin Diabetes Center Methods of diagnosing, treating, and preventing increased vascular permeability
US7875431B2 (en) 2007-02-22 2011-01-25 Genentech, Inc. Methods for detecting inflammatory bowel disease
WO2009026334A2 (en) * 2007-08-21 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
JP5566293B2 (ja) * 2007-10-04 2014-08-06 バイオノミックス リミテッド 内皮細胞マーカーおよびその使用
CN101186646B (zh) * 2007-10-26 2010-06-09 中国科学院昆明动物研究所 眼镜王蛇毒蛋白酶抑制剂及其衍生物的应用
RU2503460C2 (ru) 2007-11-07 2014-01-10 Дженентек Инк. Применение противомикробного полипептида для лечения микробных нарушений
CA2728473A1 (en) 2008-06-20 2009-12-23 National University Corporation Okayama University Antibody against oxidized ldl/.beta.2gpi complex and use of the same
US9182406B2 (en) * 2008-08-04 2015-11-10 Biodesy, Inc. Nonlinear optical detection of molecules comprising an unnatural amino acid possessing a hyperpolarizability
EP4209510B1 (en) 2008-12-09 2024-01-31 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
CN102245771B (zh) 2008-12-16 2013-04-10 诺瓦提斯公司 酵母展示系统
CA2747721C (en) 2008-12-19 2021-07-20 Baxter International Inc. Tfpi inhibitors and methods of use
US8637454B2 (en) * 2009-01-06 2014-01-28 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
WO2011038301A2 (en) 2009-09-25 2011-03-31 Xoma Technology Ltd. Screening methods
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
BR112012009409A2 (pt) 2009-10-22 2017-02-21 Genentech Inc método de identificação de uma substância inibidora, molécula antagonista, ácido nucleico isolado, vetor, célula hospedeira, método para fabricar a molécula, composição, artigo de fabricação, método de inibição de uma atividade biológica, método de tratamento de uma condição patológica, método para detectar msp em uma amostra e método para detectar hepsina em uma amostra
PE20121584A1 (es) 2009-11-30 2012-11-29 Genentech Inc Composiciones y metodos para el diagnostico y el tratamiento de tumores
ES2688093T3 (es) * 2010-01-06 2018-10-30 Dyax Corp. Proteínas de unión a calicreína plasmática
KR20130000384A (ko) 2010-02-18 2013-01-02 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 뉴레귤린 길항제 및 암의 치료에서의 그의 용도
NZ601293A (en) 2010-02-23 2014-10-31 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
EP2547355B1 (en) 2010-03-19 2017-01-11 Baxalta GmbH Tfpi inhibitors and methods of use
CN102958941A (zh) 2010-05-03 2013-03-06 霍夫曼-拉罗奇有限公司 用于肿瘤诊断和治疗的组合物和方法
WO2012071436A1 (en) 2010-11-24 2012-05-31 Genentech, Inc. Method of treating autoimmune inflammatory disorders using il-23r loss-of-function mutants
IL269565B2 (en) 2011-01-06 2024-06-01 Dyax Corp Plasma kallikrein binding proteins
WO2012129347A1 (en) 2011-03-21 2012-09-27 Biodesy, Llc Classification of kinase inhibitors using nonlinear optical techniques
US10352936B2 (en) 2011-04-14 2019-07-16 Apoplogic Pharmaceuticals, Inc. Use of tumor Fas expression to determine response to anti-cancer therapy
EP2739358B1 (en) 2011-08-01 2018-11-28 F.Hoffmann-La Roche Ag Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
WO2013040433A1 (en) 2011-09-15 2013-03-21 Genentech, Inc. Methods of promoting differentiation
MX2014004426A (es) 2011-10-15 2014-07-09 Genentech Inc Metodos de uso de antagonistas de scd1.
CA2862424A1 (en) 2012-01-18 2013-07-25 Genentech, Inc. Methods of using fgf19 modulators
HK1211037A1 (en) 2012-02-11 2016-05-13 霍夫曼-拉罗奇有限公司 R-spondin translocations and methods using the same
KR20140135198A (ko) 2012-03-16 2014-11-25 에프. 호프만-라 로슈 아게 Pak1 억제제로 흑색종을 치료하는 방법
EP2825549B1 (en) 2012-03-16 2018-10-10 F. Hoffmann-La Roche SA Engineered conformationally-stabilized proteins
US9139863B2 (en) 2012-03-16 2015-09-22 Genentech, Inc. Engineered conformationally-stabilized proteins
EP2827883B1 (en) 2012-03-21 2019-05-08 Baxalta GmbH Tfpi inhibitors and methods of use
CN104583776B (zh) 2012-04-25 2016-09-07 比奥德赛公司 用于检测蛋白质的变构调节剂的方法
WO2013170191A1 (en) 2012-05-11 2013-11-14 Genentech, Inc. Methods of using antagonists of nad biosynthesis from nicotinamide
JP6312659B2 (ja) 2012-05-31 2018-04-18 ジェネンテック， インコーポレイテッド Ｐｄ−１系結合アンタゴニスト及びｖｅｇｆアンタゴニストを用いた癌の治療方法
EP2708235A1 (en) * 2012-09-17 2014-03-19 Commissariat A L'energie Atomique Et Aux Energies Alternatives Peptide antagonists of the vasopressin-2 receptor
KR20150118159A (ko) 2013-02-22 2015-10-21 에프. 호프만-라 로슈 아게 암의 치료 방법 및 약물 내성의 예방 방법
KR20150123250A (ko) 2013-03-06 2015-11-03 제넨테크, 인크. 암 약물 내성의 치료 및 예방 방법
WO2014139130A1 (en) 2013-03-14 2014-09-18 Adagene Inc. An integrated system for library construction, affinity binder screening and expression thereof
KR20150127216A (ko) 2013-03-14 2015-11-16 제넨테크, 인크. 암의 치료 및 암 약물 내성의 예방 방법
WO2014151006A2 (en) 2013-03-15 2014-09-25 Genentech, Inc. Biomarkers and methods of treating pd-1 and pd-l1 related conditions
RU2015143437A (ru) 2013-03-15 2017-04-27 Дженентек, Инк. Способы лечения рака и предотвращения устойчивости к лекарственным препаратам для лечения рака
PE20151673A1 (es) 2013-03-15 2015-11-27 Genentech Inc POLIPEPTIDOS DE IL-22 Y PROTEINAS DE FUSION DE IL-22 Fc Y METODOS DE USO
TWI888366B (zh) 2013-07-16 2025-07-01 美商建南德克公司 利用pd-1軸結合拮抗劑及tigit抑制劑治療癌症之方法
BR112016013741A2 (pt) 2013-12-17 2017-10-03 Genentech Inc Usos de antagonistas de ligação de eixo de pd-1 e um anticorpo de anti-cd20, e kit compreendendo os mesmos
WO2015116902A1 (en) 2014-01-31 2015-08-06 Genentech, Inc. G-protein coupled receptors in hedgehog signaling
MA39347B2 (fr) * 2014-02-24 2020-05-29 Takeda Pharmaceuticals Co Protéines de fusion d'uti
EP3122782A4 (en) 2014-03-27 2017-09-13 Dyax Corp. Compositions and methods for treatment of diabetic macular edema
CN106659146B (zh) 2014-05-05 2020-06-23 再生元制药公司 人源化c5和c3动物
MX2016015163A (es) 2014-05-23 2017-03-03 Genentech Inc Biomarcadores mit y metodos para su uso.
EP3154589A1 (en) 2014-06-13 2017-04-19 Genentech, Inc. Methods of treating and preventing cancer drug resistance
JP6655074B2 (ja) 2014-06-20 2020-02-26 ジェネンテック， インコーポレイテッド シャガシンに基づく足場組成物、方法及び使用
MX2017000546A (es) 2014-07-15 2017-03-08 Genentech Inc Composiciones para el tratamiento del cancer mediante el uso de antagonistas de union al eje de pd-1 e inhibidores de mek.
US11219670B2 (en) 2014-09-05 2022-01-11 The Johns Hopkins University Targeting CAPN9/CAPNS2 activity as a therapeutic strategy for the treatment of myofibroblast differentiation and associated pathologies
FI4141032T3 (fi) 2014-11-20 2024-07-31 Hoffmann La Roche T-solua aktivoivien bispesifisten antigeeniä sitovien molekyylien ja pd-1-akselia sitovien antagonistien yhdistelmähoito
JP2017537929A (ja) 2014-12-05 2017-12-21 ジェネンテック， インコーポレイテッド Ｐｄ−１軸アンタゴニスト及びｈｐｋ１アンタゴニストを用いたがん治療のための方法及び組成物
EP3237906B8 (en) 2014-12-23 2020-10-28 Bluelight Therapeutics, Inc. Attachment of proteins to interfaces for use in nonlinear optical detection
EP3273974A4 (en) 2015-03-26 2018-11-07 Women and Infants Hospital of Rhode Island Inc. Therapy for malignant disease
EP3286227A2 (en) 2015-04-24 2018-02-28 F. Hoffmann-La Roche AG Multispecific antigen-binding proteins
CN107614516A (zh) 2015-05-11 2018-01-19 非凡食品有限公司 用于基因工程改造甲基营养型酵母的表达构建体和方法
CA3176224A1 (en) 2015-05-22 2016-12-01 Translational Drug Development Llc Benzamide and active compound compositions and methods of use
WO2016205681A1 (en) 2015-06-19 2016-12-22 University Of Rochester Septin proteins as novel biomarkers for detection and treatment of müllerian cancers
CA3000386A1 (en) 2015-09-30 2017-04-06 Merck Patent Gmbh Combination of a pd-1 axis binding antagonist and an alk inhibitor for treating alk-negative cancer
EP3371211B1 (en) 2015-11-04 2025-01-01 Icahn School of Medicine at Mount Sinai Rho-associated protein kinase ("rock") inhibitor for treating tumors and cancer, and identifying candidate subjects for such treatment
BR112018011622A2 (pt) 2015-12-11 2018-11-27 Dyax Corp método para tratar ataque de angioedema hereditário (hae) ou reduzir a taxa de ataque de hae
WO2017112954A1 (en) 2015-12-23 2017-06-29 Moonshot Pharma Llc Methods for inducing an immune response by promoting premature termination codon read-through
WO2017189730A1 (en) 2016-04-26 2017-11-02 Icahn School Of Medicine At Mount Sinai Treatment of hippo pathway mutant tumors and methods of identifying subjects as candidates for treatment
EP3481835A4 (en) 2016-07-05 2020-02-26 Blade Therapeutics, Inc. CALPAIN MODULATORS AND THERAPEUTIC USE THEREOF
JP2019534858A (ja) 2016-09-09 2019-12-05 ジェネンテック， インコーポレイテッド Ｆｒｉｚｚｌｅｄの選択的ペプチド阻害剤
SG10201912574WA (en) 2016-09-28 2020-02-27 Blade Therapeutics Inc Calpain modulators and therapeutic uses thereof
AU2017363337B2 (en) 2016-11-23 2021-07-01 Translational Drug Development, Llc Benzamide and active compound compositions and methods of use
WO2018152496A1 (en) 2017-02-17 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Compositions and methods for the diagnosis and treatment of zika virus infection
ES2975416T3 (es) 2017-02-27 2024-07-05 Regeneron Pharma Modelo humanizado de trastornos renales y hepáticos
CA3059615A1 (en) 2017-04-21 2018-10-25 Genentech, Inc. Use of klk5 antagonists for treatment of a disease
EP4230649A3 (en) 2017-04-25 2023-10-25 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Antibodies and methods for the diagnosis and treatment of epstein barr virus infection
EP3641752A4 (en) 2017-06-22 2021-03-17 Moonshot Pharma LLC METHOD OF TREATMENT OF CANCER WITH COMPOSITIONS WITH AMLEXANOX AND IMMUNE MODULATORS
WO2019018629A1 (en) 2017-07-19 2019-01-24 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services ANTIBODIES AND METHODS FOR DIAGNOSING AND TREATING INFECTION WITH HEPATITIS B VIRUS
WO2019126472A1 (en) 2017-12-22 2019-06-27 Genentech, Inc. Use of pilra binding agents for treatment of a disease
WO2020215017A1 (en) * 2019-04-17 2020-10-22 Impossible Foods Inc. Materials and methods for protein production
KR20220005568A (ko) 2019-05-09 2022-01-13 제넨테크, 인크. 항체의 제조 방법
WO2020239558A1 (en) 2019-05-24 2020-12-03 Pfizer Inc. Combination therapies using cdk inhibitors
CA3167336A1 (en) 2020-01-13 2021-07-22 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack
BR112022017718A2 (pt) 2020-03-05 2022-11-16 Diamedica Usa Inc Polipeptídeos de ulinastatina
WO2021221783A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
WO2021221782A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Chimeric antigen receptor-targeting ligands and uses thereof
EP4232040A1 (en) 2020-10-20 2023-08-30 F. Hoffmann-La Roche AG Combination therapy of pd-1 axis binding antagonists and lrrk2 inhitibors
WO2022118197A1 (en) 2020-12-02 2022-06-09 Pfizer Inc. Time to resolution of axitinib-related adverse events
CN112940095B (zh) * 2021-02-07 2022-04-15 西南大学 家蚕BmSPI51突变蛋白BmSPI51M及其制备方法和应用
EP4351582B1 (en) 2021-06-09 2025-10-08 F. Hoffmann-La Roche AG Combination of a particular braf inhibitor (paradox breaker) and a pd-1 axis binding antagonist for use in the treatment of cancer
WO2023057882A1 (en) 2021-10-05 2023-04-13 Pfizer Inc. Combinations of azalactam compounds with a pd-1 axis binding antagonist for the treatment of cancer
CN121079327A (zh) 2023-05-12 2025-12-05 基因泰克公司 用于降低抗体粘度的方法和组合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992015605A2 (en) * 1991-03-01 1992-09-17 Protein Engineering Corporation Inhibitors of human neutrophil elastase and human cathepsin g
ES2066033T3 (es) * 1989-05-13 1995-03-01 Bayer Ag Inhibidores de las proteinasas, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
CA2055425A1 (en) * 1990-11-13 1992-05-14 Hideaki Morishita Polypeptide, dna fragment encoding the same and process for producing the same, and enzyme inhibition process, drug composition and methods of treating using the same
WO1993009233A2 (en) * 1991-10-31 1993-05-13 The Salk Institute Biotechnology/Industrial Associates Inc. Recombinant amyloid precursor protein inhibitor domain and treatment of various disease states
IL104314A0 (en) * 1992-01-07 1993-05-13 Novo Nordisk As Human kunitz-type protease inhibitor and variants thereof,their production and pharmaceutical compositions containing them
JP2769083B2 (ja) * 1993-02-22 1998-06-25 日清食品株式会社 エラスターゼ阻害活性を有する新規ペプチドおよびその製造方法
JP3570558B2 (ja) * 1993-05-01 2004-09-29 持田製薬株式会社 Ｄｎａ断片およびそれを含むベクター、該ベクターによって形質転換された形質転換体、該ベクターを用いる蛋白質の産生方法
ATE529444T1 (de) * 1994-01-11 2011-11-15 Dyax Corp Inhibitoren des humanplasmins, die sich von den kunitz domänen ableiten
JPH11504938A (ja) * 1995-05-08 1999-05-11 サイオス インク． クニッツ型プロテアーゼ阻害因子

Also Published As

Publication number Publication date
ES2255066T3 (es) 2006-06-16
WO1996020278A3 (en) 1996-10-24
EP0797666B1 (en) 2005-11-30
EP1734121A2 (en) 2006-12-20
EP1734121A3 (en) 2008-09-10
DE69534656D1 (de) 2006-01-05
DE69534656T2 (de) 2006-08-17
ATE311452T1 (de) 2005-12-15
US5663143A (en) 1997-09-02
WO1996020278A2 (en) 1996-07-04
JP3977419B2 (ja) 2007-09-19
CA2207820A1 (en) 1996-07-04
JPH10510996A (ja) 1998-10-27
EP0797666A2 (en) 1997-10-01

Similar Documents

Publication Publication Date Title
ATE311452T1 (de) Gentechnisch manipulierte menschliche kunitz domänen die menschliche neutrophile elastase hemmen
DK0397633T3 (da) Fibronectinbindende protein samt fremstilling deraf
DK0640135T3 (da) Immunoglobulinbindende proteiner, der er afledt af protein L, og anvendelser af disse
CY1112875T1 (el) Sfrp και πεπτιδικα μοτιβα που διαντιδρουν με την sfrp και μεθοδοι χρησης τους
DK1908772T3 (da) Polypeptider og polynucleinsyrer af phorphorymonas gingivalis
NO882380L (no) Fibfonektin-bindende protein, samt fremstilling derav.
ATE110742T1 (de) Peptid-verbindungen.
DE69432427D1 (de) Tomate xyloglukan endotransglykosylase
DE69032258D1 (de) Antikoagulierende Peptide
DK226889D0 (da) Alkoholpeptidderivat samt anvendelse deraf til mindskning af blodkoagulation
NO922421D0 (no) Collagenbindende protein, samt fremstilling derav
ATE177432T1 (de) Antikoagulierende peptide
ATE265221T1 (de) Modifizierte, verkürzte regulatoren des komplementsystems
FI930265A0 (fi) Antikoagulantpeptider
ATE143974T1 (de) Peptide des hiv-gag proteins, ihre herstellung und verwendung
DK0412951T3 (da) Peptider, der blokerer celle-hæftning til S-alminin
DE69810724D1 (de) Verwendung von Protein C Inhibitor zur Behandlung disseminierter intravasaler Gerinnung (DIC)
DE69003306D1 (de) Reinigung von Proteinhydrolysaten.
FI855112A7 (fi) Anti-hypertensiva oktahydro-6 -azaindolpeptidderivat.